NASDAQ:STIM Neuronetics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Neuronetics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.20 +0.04 (+0.96 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$4.17Now: $4.20▼$4.7050-Day Range$2.63MA: $4.33▼$5.8752-Week Range$1.25Now: $4.20▼$11.12Volume301,320 shsAverage Volume559,513 shsMarket Capitalization$79.22 millionP/E RatioN/ADividend YieldN/ABeta2.53 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrist customers. Neuronetics, Inc. was founded in 2003 and is headquartered in Malvern, Pennsylvania.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingNeuronetics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.33, Neuronetics has a forecasted upside of 27.0% from its current price of $4.20.Amount of Analyst CoverageNeuronetics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesNeuronetics has received 103 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNeuronetics has received 95 “underperform” votes. (Add your “underperform” vote.)Community SentimentNeuronetics has received 52.02% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Neuronetics and other stocks. Vote “Outperform” if you believe STIM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe STIM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNeuronetics does not currently pay a dividend.Dividend GrowthNeuronetics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neuronetics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.00% of the stock of Neuronetics is held by insiders.Percentage Held by Institutions57.33% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Neuronetics are expected to grow in the coming year, from ($1.59) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neuronetics is -2.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neuronetics is -2.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuronetics has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.52 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:STIM Previous Symbol CUSIPN/A CIKN/A Webwww.neurostar.com Phone610-640-4202Debt Debt-to-Equity Ratio0.11 Current Ratio1.48 Quick Ratio1.41Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$62.66 million Price / Sales1.26 Cash FlowN/A Price / Cash FlowN/A Book Value$2.57 per share Price / Book1.63Profitability EPS (Most Recent Fiscal Year)($1.58) Net Income$-29,040,000.00 Net Margins-63.77% Return on Equity-82.79% Return on Assets-37.21%Miscellaneous Employees191 Outstanding Shares18,862,000Market Cap$79.22 million Next Earnings Date11/3/2020 (Estimated) OptionableNot Optionable $4.20 +0.04 (+0.96 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive STIM News and Ratings via Email Sign-up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter. Neuronetics (NASDAQ:STIM) Frequently Asked Questions How has Neuronetics' stock been impacted by COVID-19? Neuronetics' stock was trading at $2.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, STIM shares have increased by 102.9% and is now trading at $4.20. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Neuronetics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neuronetics. When is Neuronetics' next earnings date? Neuronetics is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Neuronetics. How were Neuronetics' earnings last quarter? Neuronetics Inc (NASDAQ:STIM) posted its quarterly earnings data on Tuesday, August, 4th. The company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.51) by $0.10. Neuronetics had a negative return on equity of 82.79% and a negative net margin of 63.77%. View Neuronetics' earnings history. What price target have analysts set for STIM? 4 analysts have issued 1 year target prices for Neuronetics' shares. Their forecasts range from $4.00 to $6.00. On average, they expect Neuronetics' share price to reach $5.33 in the next year. This suggests a possible upside of 27.0% from the stock's current price. View analysts' price targets for Neuronetics. Are investors shorting Neuronetics? Neuronetics saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 618,800 shares, an increase of 8.8% from the August 15th total of 568,600 shares. Based on an average trading volume of 1,110,000 shares, the short-interest ratio is presently 0.6 days. Approximately 5.3% of the shares of the stock are short sold. View Neuronetics' Short Interest. Who are some of Neuronetics' key competitors? Some companies that are related to Neuronetics include UFP Technologies (UFPT), Repro-Med Systems (REPR), Utah Medical Products (UTMD), Iradimed (IRMD), RenovaCare (RCAR), iCAD (ICAD), Westaim (WEDXF), Accuray (ARAY), Repare Therapeutics (PYPD), TELA Bio (TELA), Liquidia Technologies (LQDA), T2 Biosystems (TTOO), Apyx Medical (APYX), Soliton (SOLY) and DarioHealth (DRIO). View all competitors. What other stocks do shareholders of Neuronetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Ibio (IBIO), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Acasti Pharma (ACST), Biocept (BIOC) and General Electric (GE). Who are Neuronetics' key executives? Neuronetics' management team includes the following people: Mr. Christopher A. Thatcher, CEO, Pres & Director (Age 54)Mr. Peter L. Donato, CFO, VP & Corp. Sec. (Age 49)Mr. Gregory Harper, VP of R&D, Operations and Product Devel. (Age 58)Ms. Cassie Hallberg, VP of MarketingMr. Daniel Guthrie, Chief Commercial Officer & VP (Age 42) When did Neuronetics IPO? (STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers. What is Neuronetics' stock symbol? Neuronetics trades on the NASDAQ under the ticker symbol "STIM." Who are Neuronetics' major shareholders? Neuronetics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Deerfield Management Company L.P. Series C (8.98%), Bridgeway Capital Management Inc. (1.36%), Bellevue Group AG (1.33%), Two Sigma Advisers LP (0.76%), Blair William & Co. IL (0.72%) and Bank of New York Mellon Corp (0.35%). Company insiders that own Neuronetics stock include Brian E Farley, Christopher Thatcher, Daniel Guthrie, Gregory Harper, Peter Donato, Stephen Furlong, Stephen M Campe and William Andrew Macan. View institutional ownership trends for Neuronetics. Which institutional investors are selling Neuronetics stock? STIM stock was sold by a variety of institutional investors in the last quarter, including Bellevue Group AG, Blair William & Co. IL, Goldman Sachs Group Inc., and Algert Global LLC. View insider buying and selling activity for Neuronetics. Which institutional investors are buying Neuronetics stock? STIM stock was acquired by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., Deerfield Management Company L.P. Series C, Jane Street Group LLC, Verition Fund Management LLC, Bank of New York Mellon Corp, Engineers Gate Manager LP, Two Sigma Advisers LP, and Bank of America Corp DE. Company insiders that have bought Neuronetics stock in the last two years include Brian E Farley, Daniel Guthrie, Gregory Harper, Stephen Furlong, Stephen M Campe, and William Andrew Macan. View insider buying and selling activity for Neuronetics. How do I buy shares of Neuronetics? Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Neuronetics' stock price today? One share of STIM stock can currently be purchased for approximately $4.20. How big of a company is Neuronetics? Neuronetics has a market capitalization of $79.22 million and generates $62.66 million in revenue each year. The company earns $-29,040,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis. Neuronetics employs 191 workers across the globe. What is Neuronetics' official website? The official website for Neuronetics is www.neurostar.com. How can I contact Neuronetics? Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at 610-640-4202 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
